/
Neurology
Parkinson Disease
34
Pipeline Programs↗
112
Active Trials↗
35
Companies Involved↗
Parkinson disease is a moderately active landscape with 34 programs across 35 companies. The most active players are Supernus Pharmaceuticals, Inc., Hillhurst Biopharmaceuticals, Inc., Appello Pharmaceuticals, Inc.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 17
Phase 212
Approved
No programs
Analysis
Modality Breakdown
97%
Small molecule
28 of 29 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 91% of 34 pipeline programs.
Analysis
Trial Status
216
clinical trials
Completed83 · 38%
Recruiting72 · 33%
Active, not recruiting18 · 8%
Not yet recruiting15 · 7%
Unknown status8 · 4%
Terminated8 · 4%
Other12 · 6%
Clinical Trials
Trial Activity
216 trials
Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease
Recruiting·—·Phase 2·NCT06679374·102 enrolled
Montelukast in Parkinson Disease
Recruiting·—·Phase 2/3·NCT06113640·60 enrolled
Page 1 of 15
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)